Summary:
- The article reports on a randomized clinical trial that evaluated the effectiveness of a new COVID-19 vaccine candidate, NVX-CoV2373, compared to placebo.
- The trial involved over 29,000 participants and found that the vaccine had an overall efficacy of 90.4% in preventing mild, moderate, or severe COVID-19 disease.
- The vaccine was well-tolerated, with no safety concerns identified, and the results support the continued development and potential authorization of this COVID-19 vaccine candidate.